DDInter758 DDInter1628
Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Fluoxetine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Fluoxetine {u} (Compound) downregulates {v} (Gene) PLK1
PLK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Fluoxetine {u} (Compound) upregulates {v} (Gene) HMGCR
HMGCR {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Fluoxetine {u} (Compound) downregulates {v} (Gene) ACOT9
ACOT9 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Fluoxetine {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Fluoxetine {u} (Compound) downregulates {v} (Gene) PLK1
PLK1 {u} (Gene) is regulated by {v} (Gene) LRRK2
LRRK2 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Fluoxetine {u} (Compound) upregulates {v} (Gene) HMGCR
HMGCR {u} (Gene) regulates {v} (Gene) DUSP4
DUSP4 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Fluoxetine {u} may lead to a major life threatening interaction when taken with {v} Nilotinib
Nilotinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Fluoxetine {u} (Compound) downregulates {v} (Gene) ACOT9
ACOT9 {u} (Gene) is regulated by {v} (Gene) FOXJ3
FOXJ3 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Fluoxetine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epirubicin
Epirubicin {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Fluoxetine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Fluoxetine (Compound) downregulates PLK1 (Gene) and PLK1 (Gene) is bound by Ruxolitinib (Compound)
Fluoxetine (Compound) upregulates HMGCR (Gene) and HMGCR (Gene) is upregulated by Ruxolitinib (Compound)
Fluoxetine (Compound) downregulates ACOT9 (Gene) and ACOT9 (Gene) is downregulated by Ruxolitinib (Compound)
Fluoxetine (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Fluoxetine (Compound) downregulates PLK1 (Gene) and PLK1 (Gene) is regulated by LRRK2 (Gene) and LRRK2 (Gene) is bound by Ruxolitinib (Compound)
Fluoxetine (Compound) upregulates HMGCR (Gene) and HMGCR (Gene) regulates DUSP4 (Gene) and DUSP4 (Gene) is upregulated by Ruxolitinib (Compound)
Fluoxetine may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Fluoxetine (Compound) downregulates ACOT9 (Gene) and ACOT9 (Gene) is regulated by FOXJ3 (Gene) and FOXJ3 (Gene) is upregulated by Ruxolitinib (Compound)
Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)